
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
Key Takeaways
- FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced/metastatic breast cancer after recurrence on adjuvant endocrine therapy or progression on metastatic endocrine regimens.
- Companion diagnostic authorization designates FoundationOne Liquid CDx to detect ESR1 mutations, operationalizing biomarker-driven selection via an FDA-authorized liquid biopsy platform.
The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
The FDA approved giredestrant (Wilserdly) plus everolimus (Afinitor) for the treatment of adult patients with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after endocrine-based adjuvant therapy, or has progressed on 1 or more endocrine-based regimens in the metastatic setting.1
The FDA also authorized the use of the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer harboring ESR1 mutations who may be eligible for treatment with giredestrant plus everolimus.
This regulatory decision was based on data from the evERA Breast Cancer (NCT05306340), a randomized, open-label multicenter trial that was conducted in 373 adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer; 207 of these patients had tumors harboring ESR1 mutations. In evERA Breast Cancer, giredestrant plus everolimus (n = 183) elicited a median PFS of 10 months (95% CI, 8.1, 12.9) vs 5.5 months (95% CI, 3.8, 5.6) with physician’s choice of endocrine therapy plus everolimus (n = 190; HR, 0.38; 95% CI, 0.27-0.54; P < .0001). The ORRs in these respective arms were 27% (95% CI, 18%-37%) and 14% (95% CI, 8%-22%).
The OS data were not mature at the time of the PFS analysis.
What was the design of evERA Breast Cancer?
Patients were randomly assigned 1:1 to receive giredestrant at 30 mg once daily or physician’s choice of endocrine therapy, which included exemestane, fulvestrant (Faslodex), or tamoxifen. Patients in both arms also received everolimus at 10 mg once daily. Pre- or perimenopausal female patients additionally received a GnRH agonist for ovarian function suppression; male patients also received a GnRH agonist, except those with bilateral orchiectomy. Patients received treatment until disease progression or unacceptable toxicity.
Investigator-assessed PFS per RECIST 1.1 criteria served as the primary end point. Additional end points included OS and ORR.
What is the safety profile of giredestrant plus everolimus?
The most common adverse effects seen in at least 20% of patients in the giredestrant/everolimus arms were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea. The most common laboratory abnormalities reported in patients in this arm were decreased hemoglobin levels, decreased lymphocyte count, decreased white blood cell count, increased aspartate aminotransferase levels, increased alanine aminotransferase levels, decreased neutrophil count, decreased platelet count, decreased calcium levels, decreased potassium levels, increased creatinine levels, and decreased sodium levels.
References
FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. FDA. November 16, 2026. Accessed November 16, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-approves-giredestrant-combination-everolimus-er-positive-her2-negative-esr1-mutated-locally
Related to this article







